JPH0533688B2 - - Google Patents

Info

Publication number: JPH0533688B2
Authority: JP; Japan
Prior art keywords: lipopolysaccharide; blood; immobilized; fiber; gram
Prior art date: 1984-10-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP59221978A

Other languages

English (en)

Japanese (ja)

Other versions

JPS61100522A (ja

Inventor

Masatomo Kodama

Tooru Tani

Shiro Saikai

Jiro Suzuki

Kazuo Teramoto

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Toray Industries Inc

Original Assignee

Toray Industries Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-10-24

Filing date

1984-10-24

Publication date

1993-05-20

1984-10-24 Application filed by Toray Industries Inc filed Critical Toray Industries Inc

1984-10-24 Priority to JP59221978A priority Critical patent/JPS61100522A/ja

1986-05-19 Publication of JPS61100522A publication Critical patent/JPS61100522A/ja

1993-05-20 Publication of JPH0533688B2 publication Critical patent/JPH0533688B2/ja

Status Granted legal-status Critical Current

Links

239000002158 endotoxin Substances 0.000 claims description 44
229920006008 lipopolysaccharide Polymers 0.000 claims description 33
210000004369 blood Anatomy 0.000 claims description 21
239000008280 blood Substances 0.000 claims description 21
241000124008 Mammalia Species 0.000 claims description 11
230000000259 anti-tumor effect Effects 0.000 claims description 9
239000010836 blood and blood product Substances 0.000 claims description 7
229940125691 blood product Drugs 0.000 claims description 7
241000187479 Mycobacterium tuberculosis Species 0.000 claims description 6
229960001438 immunostimulant agent Drugs 0.000 claims description 5
239000003022 immunostimulating agent Substances 0.000 claims description 5
230000003308 immunostimulating effect Effects 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 4
230000002238 attenuated effect Effects 0.000 claims description 3
210000005256 gram-negative cell Anatomy 0.000 claims description 2
239000000835 fiber Substances 0.000 description 17
238000000034 method Methods 0.000 description 9
206010028980 Neoplasm Diseases 0.000 description 8
108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
-1 polypropylene Polymers 0.000 description 6
102000003390 tumor necrosis factor Human genes 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
210000002966 serum Anatomy 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
239000004743 Polypropylene Substances 0.000 description 4
239000004793 Polystyrene Substances 0.000 description 4
210000002421 cell wall Anatomy 0.000 description 4
238000000605 extraction Methods 0.000 description 4
LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 4
229920001155 polypropylene Polymers 0.000 description 4
229920002223 polystyrene Polymers 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000005406 washing Methods 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000589517 Pseudomonas aeruginosa Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
231100000135 cytotoxicity Toxicity 0.000 description 3
230000003013 cytotoxicity Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
241000588832 Bordetella pertussis Species 0.000 description 2
241000589567 Brucella abortus Species 0.000 description 2
241000186216 Corynebacterium Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
241000588747 Klebsiella pneumoniae Species 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
241000588652 Neisseria gonorrhoeae Species 0.000 description 2
241000283977 Oryctolagus Species 0.000 description 2
241000588767 Proteus vulgaris Species 0.000 description 2
241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
241000607720 Serratia Species 0.000 description 2
241000607764 Shigella dysenteriae Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
241000607626 Vibrio cholerae Species 0.000 description 2
241000607447 Yersinia enterocolitica Species 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
244000052616 bacterial pathogen Species 0.000 description 2
229940056450 brucella abortus Drugs 0.000 description 2
239000000969 carrier Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
229940007042 proteus vulgaris Drugs 0.000 description 2
229940007046 shigella dysenteriae Drugs 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
241000894007 species Species 0.000 description 2
239000000126 substance Substances 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
229940118696 vibrio cholerae Drugs 0.000 description 2
229940098232 yersinia enterocolitica Drugs 0.000 description 2
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
TXNSZCSYBXHETP-UHFFFAOYSA-N 2-chloro-n-(hydroxymethyl)acetamide Chemical compound OCNC(=O)CCl TXNSZCSYBXHETP-UHFFFAOYSA-N 0.000 description 1
ISCMYZGMRHODRP-UHFFFAOYSA-N 3-(iminomethylideneamino)-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCN=C=N ISCMYZGMRHODRP-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241001464975 Cutibacterium granulosum Species 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
241000192125 Firmicutes Species 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
241000239218 Limulus Species 0.000 description 1
241000187654 Nocardia Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
241001582367 Polia Species 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
241000588769 Proteus <enterobacteria> Species 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
241000700605 Viruses Species 0.000 description 1
241000607734 Yersinia <bacteria> Species 0.000 description 1
229920000392 Zymosan Polymers 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000004087 circulation Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000002131 composite material Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
230000036541 health Effects 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
239000011259 mixed solution Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
125000000466 oxiranyl group Chemical group 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000035699 permeability Effects 0.000 description 1
KSSNXJHPEFVKHY-UHFFFAOYSA-N phenol;hydrate Chemical compound O.OC1=CC=CC=C1 KSSNXJHPEFVKHY-UHFFFAOYSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
229920013639 polyalphaolefin Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
239000000523 sample Substances 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
230000008961 swelling Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
238000010792 warming Methods 0.000 description 1

Classifications

- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

JP59221978A 1984-10-24 1984-10-24 抗腫瘍性血液製剤の製造法 Granted JPS61100522A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP59221978A JPS61100522A (ja)	1984-10-24	1984-10-24	抗腫瘍性血液製剤の製造法

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP59221978A JPS61100522A (ja)	1984-10-24	1984-10-24	抗腫瘍性血液製剤の製造法

Publications (2)

Publication Number	Publication Date
JPS61100522A JPS61100522A (ja)	1986-05-19
JPH0533688B2 true JPH0533688B2 (fr)	1993-05-20

Family

ID=16775151

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP59221978A Granted JPS61100522A (ja)	1984-10-24	1984-10-24	抗腫瘍性血液製剤の製造法

Country Status (1)

Country	Link
JP (1)	JPS61100522A (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2009051846A (ja) *	1995-06-07	2009-03-12	Cerus Corp	血液製剤からソラレンを除去するための方法およびデバイス
JPWO2004096247A1 (ja) *	2003-04-28	2006-07-13	積水化学工業株式会社	サイトカイン誘導用具及びサイトカイン誘導方法
US20060263430A1 (en) *	2003-04-28	2006-11-23	Kazuo Shinmura	instrument for inducing cytokine and method of inducing cytokine
US10688129B2 (en)	2013-11-26	2020-06-23	Central Biomedia, Inc.	Method of producing a designer blood product, method of using a designer blood product, and diet for selectively enhancing blood profile

1984
- 1984-10-24 JP JP59221978A patent/JPS61100522A/ja active Granted

Also Published As

Publication number	Publication date
JPS61100522A (ja)	1986-05-19

Publication	Publication Date	Title
Aso et al.	1985	Induction of interferon and activation of NK cells and macrophages in mice by oral administration of Ge-132, an organic germanium compound
JP2804920B2 (ja)	1998-09-30	全血及び／又は血漿から腫瘍壊死因子α及び細菌性リポ多糖類を同時体外除去する装置
US6245753B1 (en)	2001-06-12	Amphiphilic polysaccharide derivatives
JPH08500623A (ja)	1996-01-23	新規グルカン調製物
JPH0749052B2 (ja)	1995-05-31	エンドトキシン中和剤
JPH05503952A (ja)	1993-06-24	可溶性グルカン類の製造方法
Hasegawa et al.	1990	Accelerated restoration of the leukocyte number and augmented resistance against Eschericia coli in cyclophosphamide-treated rats orally administered with a hot water extract of Chlorella vulgaris
Ezeamuzie et al.	1983	A study of histamine release from human basophils and lung mast cells by products of lymphocyte stimulation
EP0090892B1 (fr)	1986-11-12	Procédé de purification d'une substance physiologiquement active ayant une activité antitumorale
CA2311670A1 (fr)	1999-06-03	Composes de type heparine, leur preparation et utilisation pour prevenir la thrombose arterielle associee a une blessure vasculaire ou a des interventions
JPH0533688B2 (fr)	1993-05-20
EP0364980B1 (fr)	1993-04-14	Conjugués de gélatine et du facteur de stimulation de colonies
JPS6019719A (ja)	1985-01-31	抗腫瘍活性を有する蛋白質
US5171738A (en)	1992-12-15	Method of treating malignant tumors
EP0107119B1 (fr)	1987-02-04	Matériau pour le traitement du sang
JPH0742233B2 (ja)	1995-05-10	血液処理剤
EP1449540A1 (fr)	2004-08-25	Substance d'induction de cytokine et instrument d'induction de cytokine
JPH0364153B2 (fr)	1991-10-04
JPH0472808B2 (fr)	1992-11-19
US4772469A (en)	1988-09-20	Production of lymphoid tissue effector cells reactive against cancer cells by means of MER, and use thereof in cancer therapy
JP2901614B2 (ja)	1999-06-07	単糖類および／またはその単糖類を有する糖結合体を含む感染症の予防・治療剤
JPH01501065A (ja)	1989-04-13	創傷治癒を刺激するための製剤、該製剤の使用方法及び製造方法
Ohi et al.	2001	Cellulose membranes suppress complement activation in patients after hemodialysis
US6908627B2 (en)	2005-06-21	Conditioned media for inhibiting growth of tumor cells
NO850152L (no)	1985-11-18	Fremgangsmaate ved fremstilling av human, endogen cancerregulerende faktor.